Skip to main content

North America Dominated the Nucleic Acid Isolation and Purification Market in Terms Of Revenue Generated in the Global Market

 Nucleic acid isolation and purification is the preliminary step in the field of molecular biology research accompanied with recombinant techniques. The nucleic acid isolation process majorly includes enzymatic digestion and mechanical and chemical disruption. On the other hand, purification consists of the combination of precipitation, chromatography, centrifugation, electrophoresis, and separation.

The process of nucleic acid isolation aids sample processing by reducing the time, significantly minimizes nucleic acid loss, and enhances experimental process efficiency and effectiveness. The obtained purified product is further used in recombinant technology methods, thereby making it suitable for targeted purposes in the field of omics research. The advantages offered by nucleic acid isolation and purification significantly aid scientists and researchers to obtain high-quality starting material for conducting downstream applications, thereby generating accurate results.

According to the market intelligence published by BIS Research the nucleic acid isolation and purification market is projected to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029. The market was estimated at $2273.9 million in 2018.

Nucleic acid isolation and purification enabled end users are expected to witness wide variety of applications, and automation has further facilitated applications such as genomic/plasmid DNA, cell-free DNA (cfDNA), viral RNA, and cell-free RNA (cfRNA). Automation in nucleic acid isolation and purification offers high throughput, further reducing sample processing time.

Factors such as increasing prevalence of genetic diseases, rising research in the field of molecular biology, growing awareness and acceptance of precision medicine worldwide, and rising research funding from government and private institutions, among others, are further supporting the adoption of automated nucleic acid isolation and purification products.

As of 2019, North America is the dominating region in terms of revenue generated in the global market. The presence of full-fledged operational units of conglomerate companies contributing to this market significantly provided help in the establishment of several emerging players, further contributing significantly to the technological innovations in the nucleic acid isolation and purification market.

In the Europe region, Germany, the U.K., and France are the dominating countries in the Europe nucleic acid isolation and purification market. Factors such as growing demand for pharmaceuticals, increasing genomic research by government and private institutions, and significant adoption of technologically advanced nucleic acid isolation products, among others, are expected to support the market growth in the forthcoming years.

The global nucleic acid isolation and purification market has a long way to go with large as well as small players operating at the global and regional levels. Some of the prominent players in this market are Promega Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Merck KGaA.

Comments

Popular posts from this blog

Chatbots Increasing Efficiency in Healthcare Market

Chatbots are one of the prominent technologies currently being integrated into the healthcare system. The chatbots are not considered as the SaMD (software as medical device) as they do not participate in clinical decision-making process, rather, they act as the personal healthcare assistant as well as the trainer for its users. Click Here To Get Detailed Description of  Chatbots in Healthcare Market The usage of chatbots in the healthcare has gained popularity since 2013, when Babylon Health, the first healthcare chatbot company of the U.K. was launched. The company offered symptom checker chatbot and has started using the same chatbot as a health checker as well. The industry comprises the bot developers, platform providers, content providers, and the interface providers. Since there are no regulatory bodies such as FDA and MHRA directly governing the usage of chatbots, launching the chatbot is convenient for the developers. New start-ups are coming up wit...

Wireless Charging Technology – Analyzing the Market Drivers and Restraints

Wireless charging technology eliminates the use of wires to power devices and enables a device to be charged automatically when placed near a transmitter. The wireless charging technology is however, not new in the world of technology, rather, has been in existence since the late 1800s. With the incorporation of the technology in smartphones, it has been experiencing a massive boost in popularity. Request the Sample @  https://bisresearch.com/requestsample?id=645&type=download According to the latest market intelligence report by BIS Research titled “ Global Wireless Charging Market - Analysis and Forecast (2018-2023) ,” the market was valued at $2.58 billion in 2017 and is projected to grow at a CAGR of 40.97%, during the forecast period and reach $20.97 billion by 2023.  The market is estimated to witness the highest growth in the Asia-Pacific (APAC) region during the forecast period (2018-2023). The wireless charging technology is not only limited to the sm...

Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells

As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc...